Reduced SMAD7 leads to overactivation of TGF-β signaling in MDS that can be reversed by a specific inhibitor of TGF-β receptor I kinase

Cancer Research

Volumn 71, Issue 3, 2011, Pages 955-963

  Zhou, Li ^a   McMahon, Christine ^a   Bhagat, Tushar ^a   Alencar, Cristina ^a   Yu, Yiting ^a   Fazzari, Melissa ^a   Sohal, Davendra ^a   Heuck, Christoph ^a   Gundabolu, Krishna ^a   Ng, Chun ^a   Mo, Yongkai ^a   Shen, Wa ^a   Wickrema, Amittha ^b   Kong, Guanghui ^a   Friedman, Ellen ^a   Sokol, Lubomir ^c   Mantzaris, Giannis ^a   Pellagatti, Andrea ^d   Boultwood, Jacqueline ^d   Platanias, Leonidas C ^e   Steidl, Ulrich ^a   Yan, Lei ^f   Yingling, Jonathan M ^f   Lahn, Michael M ^f   List, Alan ^c   Bitzer, Markus ^g   Verma, Amit ^a   more..

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e NORTHWESTERN UNIVERSITY   (United States)

^f ELI LILLY AND COMPANY   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; HEMOGLOBIN; LY 2157299; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW DEPRESSION; CD34 SELECTION; CONTROLLED STUDY; ENZYME REGULATION; ERYTHROID CELL; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; MALE; MOUSE; MYELODYSPLASTIC SYNDROME; MYELOID DENDRITIC CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTE COUNT; TISSUE MICROARRAY;

ANEMIA; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; K562 CELLS; MYELODYSPLASTIC SYNDROMES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; QUINOLINES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 79551518231     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2933     Document Type: Article

References (49)

1. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999;340:1649-60.
2. Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 1998;83:358-68.
3. Greenberg PL. Biologic nature of the myelodysplastic syndromes. Acta Haematol 1987;78Suppl 1:94-9.
4. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
5. Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995;86:268-76.
6. Greenberg PL. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res 1998;22:1123-36.
7. Westwood NB, Mufti GJ. Apoptosis in the myelodysplastic syndromes. Curr Hematol Rep 2003;2:186-92.
8. Ohshima K, Karube K, Shimazaki K, et al. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis. Leuk Lymphoma 2003;44:1339-46.
9. Zorat F, Shetty V, Dutt D, et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 2001;115:881-94.
10. Allampallam K, Shetty V, Mundle S, et al. Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol 2002;75:289-97.
11. Allampallam K, Shetty V, Hussaini S, et al. Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes. Anticancer Res 1999;19:5323-8. (Pubitemid 30103369)
12. Powers MP, Nishino H, Luo Y, et al. Polymorphisms in TGFbeta and TNFalpha are associated with the myelodysplastic syndrome phenotype. Arch Pathol Lab Med 2007;131:1789-93.
13. Akiyama T, Matsunaga T, Terui T, et al. Involvement of transforming growth factor-beta and thrombopoietin in the pathogenesis of myelodysplastic syndrome with myelofibrosis. Leukemia 2005;19:1558-66.
14. Taketazu F, Miyagawa K, Ichijo H, et al. Decreased level of transforming growth factor-beta in blood lymphocytes of patients with aplastic anemia. Growth Factors 1992;6:85-90.
15. Gyulai Z, Balog A, Borbenyi Z, Mandi Y. Genetic polymorphisms in patients with myelodysplastic syndrome. Acta Microbiol Immunol Hung 2005;52:463-75. (Pubitemid 41804788)
16. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-5.
17. Yoon SY, Li CY, Lloyd RV, Tefferi A. Bone marrow histochemical studies of fibrogenic cytokines and their receptors in myelodysplastic syndrome with myelofibrosis and related disorders. Int J Hematol 2000;72:337-42.
18. Verma A, List AF. Cytokine targets in the treatment of myelodysplastic syndromes. Curr Hematol Rep 2005;4:429-35.
19. Verma A, Deb DK, Sassano A, et al. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol 2002;168:5984-8.
20. + cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 2006;108:337-45.
21. Sternberg A, Killick S, Littlewood T, et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 2005;106:2982-91.
22. Su AI, Wiltshire T, Batalov S, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 2004;101:6062-7.
23. + hematopoietic cells expanded in a collagen I matrix. Stem Cells 2006;24:494-500.
24. Eckfeldt CE, Mendenhall EM, Flynn CM, et al. Functional analysis of human hematopoietic stem cell gene expression using zebrafish. PLoS Biol 2005;3:e254.
25. + cells in patients with the 5q- syndrome. Br J Haematol 2007;139:578-89.
26. Sanderson N, Factor V, Nagy P, et al. Hepatic expression of mature transforming growth factor beta 1 in transgenicmice results in multiple tissue lesions. Proc Natl Acad Sci U S A 1995;92:2572-6.
27. Yu L, Hebert MC, Zhang YE. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. Embo J 2002;21:3749-59. (Pubitemid 34787048)
28. Verma A, Deb DK, Sassano A, et al. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem 2002;277:7726-35.
29. Bhatia M. Molecular Signatures Orchestrating Fate of Human Hematopoietic Stem Cells Originating from Different Stages of Ontogeny. Ontario Genomics Innovation Centre, NCBI: Ottawa, Ontario, Canada; 2006. Accession No. GSE3823.
30. Sohal D, Yeatts A, Ye K, et al. Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration. PLoS ONE 2008;3:e2965.
31. Liu Z, Kobayashi K, van Dinther M, et al. VEGF and inhibitors of TGFbeta type-I receptor kinase synergistically promote blood-vessel formation by inducing alpha5-integrin expression. J Cell Sci 2009;122:3294-302.
32. Li HY, Wang Y, Heap CR, et al. Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7. J Med Chem 2006;49:2138-42.
33. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004;3:1011-22.
34. Bueno L, de Alwis DP, Pitou C, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer 2008;44:142-50.
35. Calvo-Aller E, Baslega J., Glatt S, Cleverly A, Lahn M, Arteaga CL, et al. First human dose escalation study in patients with metastatic malignancies to determine safety and pharmacokinetics of LY2157299, a small molecule inhibitor of the transforming growth factor-beta receptor I kinase. J Clin Oncol 2008;26Suppl. Abstract 14554.
36. Zhou L, Nguyen AN, Sohal D, et al. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood 2008;112:3434-43.
37. Akhurst RJ. TGF beta signaling in health and disease. Nat Genet 2004;36:790-2.
38. Tenesa A, Farrington SM, Prendergast JG, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet 2008;40:631-7.
39. Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010;207:1589-97.
40. He W, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MA, Massague J. Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell 2006;125:929-41. (Pubitemid 43795187)
41. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007;110:4385-95.
42. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 2008;451:335-9.
43. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008;111:1534-42.
44. Kroeger H, Jelinek J, Estecio MR, et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 2008;112:1366-73.
45. Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009;114:3448-58.
46. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009;113:1315-25.
47. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005;19:2783-810.
48. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003;113:685-700.
49. Akhurst RJ. Large- and small-molecule inhibitors of transforming growth factor-beta signaling. Curr Opin Investig Drugs 2006;7:513-21.